Skip to content

Study · Randomized controlled trial · n = 500 · 2022

19 results

Abaloparatide Effects on Cortical Volumetric BMD and Estimated Strength Indices of Hip Subregions by 3D-DXA in Women With Postmenopausal Osteoporosis.

Winzenrieth R, Humbert L, Boxberger JI, Weiss RJ, Wang Y, Kostenuik P

Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry25 Nov 2021Cited by 19 (Europe PMC)

PMID35033435 (opens in a new tab)DOI10.1016/j.jocd.2021.11.007 (opens in a new tab)PepBankPUB-35033435
Publisher pagePubMedAsk about this study
Jump to 19 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study19

19 results from studies that gave the peptide. 19 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, abaloparatide increased femoral neck areal BMD versus placebo at both assessments.

    In plain wordsIn women with osteoporosis, abaloparatide increased femoral neck bone density more than placebo at both assessments.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseFemoral neck areal BMD
    Study

    n = 500

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 µg daily · subcutaneous · 6 and 18 monthsAs given in this study (human).

    Source sentences

    Summary
    Femoral neck, trochanter, and shaft aBMD increased in the abaloparatide and teriparatide groups at mo 6 and 18 vs placebo, with greater increases for abaloparatide vs teriparatide at the femoral neck at mo 6 and the shaft at mo 6 and 18.
    1 context sentence
    Summary · context
    Randomly selected subjects from ACTIVE (n = 250/treatment group) who received 18 mo of placebo, abaloparatide 80 µg, or open-label teriparatide 20 µg by daily subcutaneous injection underwent hip DXA at baseline, and mo 6 and 18 of treatment.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, abaloparatide increased trochanter areal BMD versus placebo at both assessments.

    In plain wordsIn women with osteoporosis, abaloparatide increased trochanter bone density more than placebo at both assessments.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseTrochanter areal BMD
    Study

    n = 500

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 µg daily · subcutaneous · 6 and 18 monthsAs given in this study (human).

    Source sentences

    Summary
    Femoral neck, trochanter, and shaft aBMD increased in the abaloparatide and teriparatide groups at mo 6 and 18 vs placebo, with greater increases for abaloparatide vs teriparatide at the femoral neck at mo 6 and the shaft at mo 6 and 18.
    1 context sentence
    Summary · context
    Randomly selected subjects from ACTIVE (n = 250/treatment group) who received 18 mo of placebo, abaloparatide 80 µg, or open-label teriparatide 20 µg by daily subcutaneous injection underwent hip DXA at baseline, and mo 6 and 18 of treatment.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, abaloparatide increased femoral shaft areal BMD versus placebo at both assessments.

    In plain wordsIn women with osteoporosis, abaloparatide increased femoral shaft bone density more than placebo at both assessments.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseFemoral shaft areal BMD
    Study

    n = 500

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 µg daily · subcutaneous · 6 and 18 monthsAs given in this study (human).

    Source sentences

    Summary
    Femoral neck, trochanter, and shaft aBMD increased in the abaloparatide and teriparatide groups at mo 6 and 18 vs placebo, with greater increases for abaloparatide vs teriparatide at the femoral neck at mo 6 and the shaft at mo 6 and 18.
    1 context sentence
    Summary · context
    Randomly selected subjects from ACTIVE (n = 250/treatment group) who received 18 mo of placebo, abaloparatide 80 µg, or open-label teriparatide 20 µg by daily subcutaneous injection underwent hip DXA at baseline, and mo 6 and 18 of treatment.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, abaloparatide increased femoral neck areal BMD more than teriparatide at the early assessment.

    In plain wordsIn women with osteoporosis, abaloparatide increased femoral neck bone density more than teriparatide at the early assessment.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseFemoral neck areal BMD
    Study

    n = 500

    Comparator
    Teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 µg daily · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Femoral neck, trochanter, and shaft aBMD increased in the abaloparatide and teriparatide groups at mo 6 and 18 vs placebo, with greater increases for abaloparatide vs teriparatide at the femoral neck at mo 6 and the shaft at mo 6 and 18.
    1 context sentence
    Summary · context
    Randomly selected subjects from ACTIVE (n = 250/treatment group) who received 18 mo of placebo, abaloparatide 80 µg, or open-label teriparatide 20 µg by daily subcutaneous injection underwent hip DXA at baseline, and mo 6 and 18 of treatment.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, abaloparatide increased femoral shaft areal BMD more than teriparatide at both assessments.

    In plain wordsIn women with osteoporosis, abaloparatide increased femoral shaft bone density more than teriparatide at both assessments.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseFemoral shaft areal BMD
    Study

    n = 500

    Comparator
    Teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 µg daily · subcutaneous · 6 and 18 monthsAs given in this study (human).

    Source sentences

    Summary
    Femoral neck, trochanter, and shaft aBMD increased in the abaloparatide and teriparatide groups at mo 6 and 18 vs placebo, with greater increases for abaloparatide vs teriparatide at the femoral neck at mo 6 and the shaft at mo 6 and 18.
    1 context sentence
    Summary · context
    Randomly selected subjects from ACTIVE (n = 250/treatment group) who received 18 mo of placebo, abaloparatide 80 µg, or open-label teriparatide 20 µg by daily subcutaneous injection underwent hip DXA at baseline, and mo 6 and 18 of treatment.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, abaloparatide significantly increased femoral neck trabecular volumetric BMD versus placebo.

    In plain wordsIn women with osteoporosis, abaloparatide increased femoral neck trabecular bone density more than placebo.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseFemoral neck trabecular volumetric BMD
    Study

    n = 500

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 µg daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    All 3 subregions showed similar significant increases in Tb.vBMD with abaloparatide and teriparatide vs placebo, whereas Ct.vBMD of all 3 subregions showed greater increases after 18 mo of abaloparatide vs teriparatide.
    1 context sentence
    Summary · context
    Randomly selected subjects from ACTIVE (n = 250/treatment group) who received 18 mo of placebo, abaloparatide 80 µg, or open-label teriparatide 20 µg by daily subcutaneous injection underwent hip DXA at baseline, and mo 6 and 18 of treatment.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, abaloparatide significantly increased trochanter trabecular volumetric BMD versus placebo.

    In plain wordsIn women with osteoporosis, abaloparatide increased trochanter trabecular bone density more than placebo.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseTrochanter trabecular volumetric BMD
    Study

    n = 500

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 µg daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    All 3 subregions showed similar significant increases in Tb.vBMD with abaloparatide and teriparatide vs placebo, whereas Ct.vBMD of all 3 subregions showed greater increases after 18 mo of abaloparatide vs teriparatide.
    1 context sentence
    Summary · context
    Randomly selected subjects from ACTIVE (n = 250/treatment group) who received 18 mo of placebo, abaloparatide 80 µg, or open-label teriparatide 20 µg by daily subcutaneous injection underwent hip DXA at baseline, and mo 6 and 18 of treatment.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, abaloparatide significantly increased shaft trabecular volumetric BMD versus placebo.

    In plain wordsIn women with osteoporosis, abaloparatide increased shaft trabecular bone density more than placebo.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseShaft trabecular volumetric BMD
    Study

    n = 500

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 µg daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    All 3 subregions showed similar significant increases in Tb.vBMD with abaloparatide and teriparatide vs placebo, whereas Ct.vBMD of all 3 subregions showed greater increases after 18 mo of abaloparatide vs teriparatide.
    1 context sentence
    Summary · context
    Randomly selected subjects from ACTIVE (n = 250/treatment group) who received 18 mo of placebo, abaloparatide 80 µg, or open-label teriparatide 20 µg by daily subcutaneous injection underwent hip DXA at baseline, and mo 6 and 18 of treatment.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, abaloparatide and teriparatide produced similar increases in femoral neck trabecular volumetric BMD.

    In plain wordsIn women with osteoporosis, abaloparatide and teriparatide produced similar increases in femoral neck trabecular bone density.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeFemoral neck trabecular volumetric BMD
    Study

    n = 500

    Comparator
    Teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 µg daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    All 3 subregions showed similar significant increases in Tb.vBMD with abaloparatide and teriparatide vs placebo, whereas Ct.vBMD of all 3 subregions showed greater increases after 18 mo of abaloparatide vs teriparatide.
    1 context sentence
    Summary · context
    Randomly selected subjects from ACTIVE (n = 250/treatment group) who received 18 mo of placebo, abaloparatide 80 µg, or open-label teriparatide 20 µg by daily subcutaneous injection underwent hip DXA at baseline, and mo 6 and 18 of treatment.
  10. 10HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, abaloparatide and teriparatide produced similar increases in trochanter trabecular volumetric BMD.

    In plain wordsIn women with osteoporosis, abaloparatide and teriparatide produced similar increases in trochanter trabecular bone density.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeTrochanter trabecular volumetric BMD
    Study

    n = 500

    Comparator
    Teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 µg daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    All 3 subregions showed similar significant increases in Tb.vBMD with abaloparatide and teriparatide vs placebo, whereas Ct.vBMD of all 3 subregions showed greater increases after 18 mo of abaloparatide vs teriparatide.
    1 context sentence
    Summary · context
    Randomly selected subjects from ACTIVE (n = 250/treatment group) who received 18 mo of placebo, abaloparatide 80 µg, or open-label teriparatide 20 µg by daily subcutaneous injection underwent hip DXA at baseline, and mo 6 and 18 of treatment.
  11. 11HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, abaloparatide and teriparatide produced similar increases in shaft trabecular volumetric BMD.

    In plain wordsIn women with osteoporosis, abaloparatide and teriparatide produced similar increases in shaft trabecular bone density.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeShaft trabecular volumetric BMD
    Study

    n = 500

    Comparator
    Teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 µg daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    All 3 subregions showed similar significant increases in Tb.vBMD with abaloparatide and teriparatide vs placebo, whereas Ct.vBMD of all 3 subregions showed greater increases after 18 mo of abaloparatide vs teriparatide.
    1 context sentence
    Summary · context
    Randomly selected subjects from ACTIVE (n = 250/treatment group) who received 18 mo of placebo, abaloparatide 80 µg, or open-label teriparatide 20 µg by daily subcutaneous injection underwent hip DXA at baseline, and mo 6 and 18 of treatment.
  12. 12HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, abaloparatide increased femoral neck cortical volumetric BMD more than teriparatide.

    In plain wordsIn women with osteoporosis, abaloparatide increased femoral neck cortical bone density more than teriparatide.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseFemoral neck cortical volumetric BMD
    Study

    n = 500

    Comparator
    Teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 µg daily · subcutaneous · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    All 3 subregions showed similar significant increases in Tb.vBMD with abaloparatide and teriparatide vs placebo, whereas Ct.vBMD of all 3 subregions showed greater increases after 18 mo of abaloparatide vs teriparatide.
    1 context sentence
    Summary · context
    Randomly selected subjects from ACTIVE (n = 250/treatment group) who received 18 mo of placebo, abaloparatide 80 µg, or open-label teriparatide 20 µg by daily subcutaneous injection underwent hip DXA at baseline, and mo 6 and 18 of treatment.
  13. 13HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, abaloparatide increased trochanter cortical volumetric BMD more than teriparatide.

    In plain wordsIn women with osteoporosis, abaloparatide increased trochanter cortical bone density more than teriparatide.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseTrochanter cortical volumetric BMD
    Study

    n = 500

    Comparator
    Teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 µg daily · subcutaneous · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    All 3 subregions showed similar significant increases in Tb.vBMD with abaloparatide and teriparatide vs placebo, whereas Ct.vBMD of all 3 subregions showed greater increases after 18 mo of abaloparatide vs teriparatide.
    1 context sentence
    Summary · context
    Randomly selected subjects from ACTIVE (n = 250/treatment group) who received 18 mo of placebo, abaloparatide 80 µg, or open-label teriparatide 20 µg by daily subcutaneous injection underwent hip DXA at baseline, and mo 6 and 18 of treatment.
  14. 14HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, abaloparatide increased shaft cortical volumetric BMD more than teriparatide.

    In plain wordsIn women with osteoporosis, abaloparatide increased shaft cortical bone density more than teriparatide.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseShaft cortical volumetric BMD
    Study

    n = 500

    Comparator
    Teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 µg daily · subcutaneous · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    All 3 subregions showed similar significant increases in Tb.vBMD with abaloparatide and teriparatide vs placebo, whereas Ct.vBMD of all 3 subregions showed greater increases after 18 mo of abaloparatide vs teriparatide.
    1 context sentence
    Summary · context
    Randomly selected subjects from ACTIVE (n = 250/treatment group) who received 18 mo of placebo, abaloparatide 80 µg, or open-label teriparatide 20 µg by daily subcutaneous injection underwent hip DXA at baseline, and mo 6 and 18 of treatment.
  15. 15HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, abaloparatide improved biomechanical parameters in all hip subregions versus placebo.

    In plain wordsIn women with osteoporosis, abaloparatide improved hip subregion biomechanical parameters more than placebo.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    Direction not reportedHip subregion biomechanical parameters
    Study

    n = 500

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 µg daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Biomechanical parameters improved in all subregions with abaloparatide and teriparatide vs placebo, with greater improvements in CSMI and Z of the femoral neck and lower shaft after 6 and 18 mo of abaloparatide vs teriparatide.
    1 context sentence
    Summary · context
    Randomly selected subjects from ACTIVE (n = 250/treatment group) who received 18 mo of placebo, abaloparatide 80 µg, or open-label teriparatide 20 µg by daily subcutaneous injection underwent hip DXA at baseline, and mo 6 and 18 of treatment.
  16. 16HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, abaloparatide improved femoral neck cross-sectional moment of inertia more than teriparatide at both assessments.

    In plain wordsIn women with osteoporosis, abaloparatide improved femoral neck resistance to bending more than teriparatide at both assessments.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseFemoral neck cross-sectional moment of inertia
    Study

    n = 500

    Comparator
    Teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 µg daily · subcutaneous · 6 and 18 monthsAs given in this study (human).

    Source sentences

    Summary
    Biomechanical parameters improved in all subregions with abaloparatide and teriparatide vs placebo, with greater improvements in CSMI and Z of the femoral neck and lower shaft after 6 and 18 mo of abaloparatide vs teriparatide.
    1 context sentence
    Summary · context
    Randomly selected subjects from ACTIVE (n = 250/treatment group) who received 18 mo of placebo, abaloparatide 80 µg, or open-label teriparatide 20 µg by daily subcutaneous injection underwent hip DXA at baseline, and mo 6 and 18 of treatment.
  17. 17HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, abaloparatide improved lower shaft cross-sectional moment of inertia more than teriparatide at both assessments.

    In plain wordsIn women with osteoporosis, abaloparatide improved lower shaft resistance to bending more than teriparatide at both assessments.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseLower shaft cross-sectional moment of inertia
    Study

    n = 500

    Comparator
    Teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 µg daily · subcutaneous · 6 and 18 monthsAs given in this study (human).

    Source sentences

    Summary
    Biomechanical parameters improved in all subregions with abaloparatide and teriparatide vs placebo, with greater improvements in CSMI and Z of the femoral neck and lower shaft after 6 and 18 mo of abaloparatide vs teriparatide.
    1 context sentence
    Summary · context
    Randomly selected subjects from ACTIVE (n = 250/treatment group) who received 18 mo of placebo, abaloparatide 80 µg, or open-label teriparatide 20 µg by daily subcutaneous injection underwent hip DXA at baseline, and mo 6 and 18 of treatment.
  18. 18HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, abaloparatide improved femoral neck section modulus more than teriparatide at both assessments.

    In plain wordsIn women with osteoporosis, abaloparatide improved femoral neck section modulus more than teriparatide at both assessments.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseFemoral neck section modulus
    Study

    n = 500

    Comparator
    Teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 µg daily · subcutaneous · 6 and 18 monthsAs given in this study (human).

    Source sentences

    Summary
    Biomechanical parameters improved in all subregions with abaloparatide and teriparatide vs placebo, with greater improvements in CSMI and Z of the femoral neck and lower shaft after 6 and 18 mo of abaloparatide vs teriparatide.
    1 context sentence
    Summary · context
    Randomly selected subjects from ACTIVE (n = 250/treatment group) who received 18 mo of placebo, abaloparatide 80 µg, or open-label teriparatide 20 µg by daily subcutaneous injection underwent hip DXA at baseline, and mo 6 and 18 of treatment.
  19. 19HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, abaloparatide improved lower shaft section modulus more than teriparatide at both assessments.

    In plain wordsIn women with osteoporosis, abaloparatide improved lower shaft section modulus more than teriparatide at both assessments.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseLower shaft section modulus
    Study

    n = 500

    Comparator
    Teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 µg daily · subcutaneous · 6 and 18 monthsAs given in this study (human).

    Source sentences

    Summary
    Biomechanical parameters improved in all subregions with abaloparatide and teriparatide vs placebo, with greater improvements in CSMI and Z of the femoral neck and lower shaft after 6 and 18 mo of abaloparatide vs teriparatide.
    1 context sentence
    Summary · context
    Randomly selected subjects from ACTIVE (n = 250/treatment group) who received 18 mo of placebo, abaloparatide 80 µg, or open-label teriparatide 20 µg by daily subcutaneous injection underwent hip DXA at baseline, and mo 6 and 18 of treatment.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.